The Lancet Haematology· Thomas N Williams, Luke R Smart, George Tomlinson, Brígida Santos, Léon Tshilolo, Peter Olupot-Olupot, Banu Aygun, Susan E Stuber, Adam Lane, Teresa Latham, Russell E Ware, REACH Investigators·· 2026-10-08AI 评分49
REACH 回顾性队列:撒哈拉以南非洲接受羟基脲治疗的镰状细胞贫血患儿感染发生率未升高
[Articles] Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial
AI 导读
REACH 试验的回顾性队列分析显示,在安哥拉、刚果(金)、肯尼亚和乌干达接受口服羟基脲治疗的镰状细胞贫血患儿,治疗期间临床诊断感染的发生率与严重程度未见升高。研究团队认为,即使按最大耐受剂量给药,羟基脲也未增加患儿因感染致病或死亡的风险。
来源:The Lancet Haematology · thelancet.com